^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    samatatug zovodotin (XB002)

    i
    Other names: XB002, ICON-2
    Associations

    News

    Trials
    Company:
    Exelixis
    Drug class:
    Microtubule inhibitor, Human TF-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    8ms
    Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (clinicaltrials.gov)
    P1, N=269, Completed, Exelixis | Active, not recruiting --> Completed | N=573 --> 269 | Trial completion date: Jul 2025 --> Mar 2025
    Trial completion • Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • ER negative
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • samatatug zovodotin (XB002)
    1year
    Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (clinicaltrials.gov)
    P1, N=573, Active, not recruiting, Exelixis | Trial completion date: Feb 2025 --> Jul 2025
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • ER negative • PGR negative
    |
    Opdivo (nivolumab) • samatatug zovodotin (XB002)
    over1year
    Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (clinicaltrials.gov)
    P1, N=573, Active, not recruiting, Exelixis | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Feb 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Opdivo (nivolumab) • samatatug zovodotin (XB002)
    almost2years
    Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor–targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort. (ASCO-GU 2024)
    ENA 2022. Clinical trial information: NCT04925284.
    Clinical • P1 data • Metastases
    |
    samatatug zovodotin (XB002)
    almost2years
    Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts. (ASCO-GI 2024)
    JEWEL-101 (NCT04925284) is a phase 1, dose-escalation and multi-cohort expansion study evaluating XB002 alone and in combination with nivolumab or bevacizumab in pts with advanced solid tumors. ENA 2022. Clinical trial information: NCT04925284.
    Clinical • P1 data • Metastases
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • samatatug zovodotin (XB002)
    over3years
    Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (clinicaltrials.gov)
    P1, N=451, Recruiting, Exelixis | N=199 --> 451
    Enrollment change • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • ER negative • PGR negative
    |
    Opdivo (nivolumab) • samatatug zovodotin (XB002)